Biofarm Sa · BVB:BIO
Biofarm Sa — H1 2023 Earnings Presentation
21 slides from Biofarm Sa's earnings presentation, Jun 30, 2023
Slide 1: Presentation of Financial Statements 30 June 2023
PRESENTATION OF FINANCIAL STATEMENTS 30 June 2023
Slide 2: About this Presentation
About this Presentation Presenting the financial statements to shareholders is essential to provide a clear and detailed picture of the company's financial position. These presentations should provide a comprehensive view of the company's financial performance and should provide shareholders with th
Slide 3: Company Details
Company Details Brand: Name of the commercial company: Biofarm S.A. Main object of activity: Manufacture of pharmaceutical preparations Registered office: Str. Logofătul Tăutu nr. 99, Bucharest, sector 3 Production units: Str. Logofătul Tăutu nr. 99, Bucharest, sector 3 Str. Drumul Gura Bădicului nr
Slide 4: About us
About us The most famous Biofarm® brands have written history, and the fact that after so It is precisely this expertise and permanent consultation of our consumers that forces us to go 101 years of life have taught us many things: many years since their appearance they are further and expand our ra
Slide 5: History
History 1964 1928 1956 1959 1965 1978 1921 Cavit 1969 Carmol Year of Extension Triferment & Anghirol Colebil Insulin Production The oldest stories about Cavit Year of At a time when the Two of the most famous are already 5 decades old and Year of Biofarm Establishment pharmaceutical industry Biofarm
Slide 6: General Manager's Declarations
General Manager’s Declarations Biofarm estimates for this year a turnover of approximately lei 325 million, which represents a 17% increase, as compared to last year. Also, the estimated EBITDA for this year is of lei 105 million, 16% more than last year. In addition, Biofarm estimates for this year
Slide 7: Mission, vision and values
Mission, vision and values Our Vision Our Mission Our vision is for Biofarm® products to be the first The mission of Biofarm® is to do good to those around choice for those who want well-being and are us through continuous improvement, with respect for concerned about their health, because we, at th
Slide 8: Responsibility towards our consumers guides us in every action
Responsibility towards our consumers guides us in every action we undertake and in every business decision. We treat each consumer and the health problem they We think responsibly and feel responsible for each face with care and respect, we accompany all those person who uses a Biofarm product. The
Slide 9: Certificates
Certificates Biofarm SA is an authorized manufacturer of pharmaceutical preparations with 2 operational units. In June 2021, the new production unit in Str. Drumul Gura Bădicului nr. 202-232, Bucharest, sector 3 was inspected by ANMDMR (National Agency for Medicines and Medical Devices of Romania) a
Slide 10: Brands
Brands Biofarm brands were created to respond to the needs and expectations of our customers, differentiating our own products from those of competing companies. They create recognition, give value to the product and the company, and are a promise of quality, professionalism, efficiency and accessib
Slide 11: Brands
Brands Biofarm S.A. is one of the first ten manufacturers of drugs and food supplements in Romania. In more than 100 years of uninterrupted activity, Biofarm has always focused on aligning with market requirements and patient’s needs, being a company always oriented towards innovation and facilitati
Slide 12: Biofarm's Performance
Biofarm’s Performance The performance of our company is mainly determined by the following: Strategic Development Financial Evolution Evolution on the Stock Market 12
Slide 13: Strategic Development: Worldwide Strategy
Strategic Development Worldwide Strategy We regularly review and monitor the performance and effectiveness of our global strategies to ensure we stay on track and achieve our long-term goals. Thus, the global strategy remains unchanged and begins by prioritizing strategic initiatives for the greates
Slide 14: Strategic Development: Local Strategy
Strategic Development Local Strategy Understanding the specifics of businesses and the local market is essential to develop an effective strategy tailored to our clients' needs. Our efforts to contribute to the increase of competitiveness and quality in the sector in which we operate are essential f
Slide 15: Financial Evolution: Profit and loss account
Financial Evolution Profit and loss account and other income The net income from sales achieved in the first half of 2023 was of lei 162,172,118, increasing by 17%, as compared to the same period of 2022. The net operating result in the first half of 2023 increased by lei 1,370,530, approximately 3%
Slide 16: Financial Evolution: Assets, debts and equities
Financial Evolution Statement of assets, debts and equities In the first 6 months of 2023, the value of ongoing purchases of tangible assets was of lei 7,552,560. Tangible assets, respectively "Technical installations and machines" increased by lei 3,065,221 due to the commissioning of new productio
Slide 17: Financial Evolution: Capital
Financial Evolution Statement of the financial position – Capital The subscribed share capital of the company as at 30 June 2023 was of lei 98,537,535, the nominal value of a share was of lei 0.1/share. The company has a number of 985,375,350 shares that give equal rights to the company's shareholde
Slide 18: Financial Evolution: Statement of cash flows
Financial Evolution Statement of cash flows Most of the cash flows are generated from the company's core activity, the production and marketing of medicines for human use, NACE code 2120 "Manufacture of pharmaceutical preparations". During the first 6 months of 2023, Biofarm SA generated a cash infl
Slide 19: Information about the Stock Exchange
Information about the Stock Exchange The securities issued by Biofarm S.A. are traded on the main market at the Bucharest Stock Exchange, Premium category, BIO symbol. The shareholding structure on 30.06.2023 was the following: Shareholder Shares Percent S.I.F. MUNTENIA BUCHAREST 508,231,323 51.5774
Slide 20: Information about the Stock Exchange
Information about the Stock Exchange The shares of BIOFARM S.A. were traded on the RASDAQ Market, in the basic category, starting from 19.11.1996. In accordance with the Decision of the Extraordinary General Meeting of Shareholders No. 40 of 24.03.2005, the start of the necessary operations for the
Slide 21: Evolution on the Stock Exchange
Evolution on the Stock Exchange During the first 6 months of 2023, the stock market share increased from the year’s opening price of approximately lei 0.60/share to lei 0.66/share. An increase of 6 bani that translates into 10 percentage points within the period. 21